Deucravacitinib Matching Placebo

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Plaque Psoriasis

Phase 3

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Active, not recruitingNCT06143878

Janssen Research & Development, LLCPlaque Psoriasis

Start: 2024-02-01End: 2027-06-01Updated: 2026-07-07

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Active, not recruitingNCT06220604

Janssen Research & Development, LLCPlaque Psoriasis

Start: 2024-03-09End: 2027-09-20Updated: 2026-08-31

Related Papers

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials

Dermatology and Therapy2026-08-28

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

2026-07-03

FDA approves IcotydeTM (Icotrokinra): a novel IL-23 receptor antagonist for plaque psoriasis

Annals of Medicine and Surgery2026-06-10

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.

2025-09-181 citations